The significant contribution of SDC1 to the promotion of tumorigenesis and metastasis is increasingly acknowledged across various cancer types, including GBM [53], PDAC [54], Multiple myeloma [55], Breast cancer [56], hepatocellular carcinoma [57], and Hodgkin’s lymphoma [58], suggesting the exciting potential of SDC1 as an innovative target for cancer treatment. The gene discussed is SDC1; the disease is plasma cell myeloma.